Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial

Background and aimsAllergic asthma has a considerable burden on the quality of life. A significant portion of moderate-to-severe allergic asthma patients need omalizumab, an anti-immunoglobulin-E monoclonal antibody, as an add-on therapy. In this phase III clinical trial P043 (Zerafil®, CinnaGen, Ir...

Повний опис

Бібліографічні деталі

Автори:	Mostafa Ghanei, Babak Ghalebaghi, Ramin Sami, Mehdi Torabizadeh, Majid Mirsadraee, Babak Amra, Marzieh Tavakol, Hanieh Raji, Morteza Fallahpour, Arda Kiani, Atefeh Abedini, Farahzad Jabbari Azad, Seyed Alireza Mahdaviani, Davood Attaran, Mohammad Samet, Sasan Tavana, Maryam Haddadzadeh shoushtari, Javad Nazari, FatemehAlsadat AghaeiMeybodi, Mohammad Reza Fazlollahi, Ramin Ghasemi, Araz Sabzvari, Hamidreza Kafi, Esmaeil Idani
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2024-07-01
Серія:	Frontiers in Immunology
Предмети:	asthma omalizumab biosimilar IgE allergic
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1425906/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!